University Of Notre Dame Du Lac Bei Gene, Ltd. Transaction History

University Of Notre Dame Du Lac

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$113.99 - $146.86 $2.19 Million - $2.82 Million	-19,173 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$122.82 - $151.83 $81,306 - $100,511	662 Added 3.58%	19,173 $2.53 Million
Q4 2018 Feb 13, 2019	BUY	$107.01 - $175.15 $167,470 - $274,109	1,565 Added 9.24%	18,511 $2.6 Million
Q3 2018 Nov 13, 2018	BUY	$152.62 - $189.66 $342,784 - $425,976	2,246 Added 15.28%	16,946 $2.92 Million
Q2 2018 Aug 14, 2018	SELL	$152.5 - $216.77 $929,640 - $1.32 Million	-6,096 Reduced 29.31%	14,700 $2.26 Million
Q1 2018 May 15, 2018	SELL	$97.41 - $177.22 $1.18 Million - $2.15 Million	-12,104 Reduced 36.79%	20,796 $3.49 Million
Q4 2017 Feb 13, 2018	SELL	$79.6 - $114.73 $215,158 - $310,115	-2,703 Reduced 7.59%	32,900 $3.22 Million
Q3 2017 Nov 13, 2017	BUY	$66.19 - $103.46 $2.36 Million - $3.68 Million	35,603	35,603 $3.68 Million

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of University Of Notre Dame Du Lac, based on Form 13F filings with the SEC.

Stay updated on University Of Notre Dame Du Lac with notifications on news.